Mabion S.A. (MAB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Mabion S.A. (MAB) has a cash flow conversion efficiency ratio of -0.308x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (zł-12.06 Million ≈ $-3.32 Million USD) by net assets (zł39.09 Million ≈ $10.76 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Mabion S.A. balance sheet quality to measure how much of total assets are equity-financed.
Mabion S.A. - Cash Flow Conversion Efficiency Trend (2009–2025)
This chart illustrates how Mabion S.A.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Mabion S.A. (MAB) cash flow quality to evaluate the quality of earnings relative to operating cash generation.
Mabion S.A. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Mabion S.A. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Orbit Garant Drilling Inc.
TO:OGD
|
-0.033x |
|
Kuk Dong
KO:005320
|
-0.103x |
|
AfroCentric Investment Corp
JSE:ACT
|
0.106x |
|
Kartal Yenilenebilir Enerji Uretim AS
IS:KARYE
|
-0.059x |
|
NDFOS Co. Ltd
KQ:238090
|
-0.005x |
|
Australian Mines Ltd
AU:AUZ
|
-0.017x |
|
4Mass SA
WAR:4MS
|
0.110x |
|
Compal Broadband Networks Inc
TW:6674
|
-0.089x |
Annual Cash Flow Conversion Efficiency for Mabion S.A. (2009–2025)
The table below shows the annual cash flow conversion efficiency of Mabion S.A. from 2009 to 2025. For the full company profile with market capitalisation and key ratios, see market value of Mabion S.A..
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | zł48.83 Million ≈ $13.44 Million |
zł-41.59 Million ≈ $-11.45 Million |
-0.852x | -338.12% |
| 2024-12-31 | zł111.44 Million ≈ $30.67 Million |
zł39.86 Million ≈ $10.97 Million |
0.358x | +1905.77% |
| 2023-12-31 | zł117.78 Million ≈ $32.41 Million |
zł-2.33 Million ≈ $-642.08K |
-0.020x | -103.90% |
| 2022-12-31 | zł76.51 Million ≈ $21.06 Million |
zł38.84 Million ≈ $10.69 Million |
0.508x | +182.24% |
| 2021-12-31 | zł53.31 Million ≈ $14.67 Million |
zł-32.91 Million ≈ $-9.06 Million |
-0.617x | -235.56% |
| 2020-12-31 | zł-77.39 Million ≈ $-21.30 Million |
zł-35.24 Million ≈ $-9.70 Million |
0.455x | -70.89% |
| 2019-12-31 | zł-21.58 Million ≈ $-5.94 Million |
zł-33.76 Million ≈ $-9.29 Million |
1.564x | +269.28% |
| 2018-12-31 | zł42.14 Million ≈ $11.60 Million |
zł-38.94 Million ≈ $-10.72 Million |
-0.924x | -192.46% |
| 2017-12-31 | zł-54.16 Million ≈ $-14.91 Million |
zł-54.13 Million ≈ $-14.90 Million |
0.999x | +124.49% |
| 2016-12-31 | zł3.73 Million ≈ $1.03 Million |
zł-15.22 Million ≈ $-4.19 Million |
-4.082x | -1433.70% |
| 2015-12-31 | zł127.64 Million ≈ $35.13 Million |
zł-33.97 Million ≈ $-9.35 Million |
-0.266x | -988.98% |
| 2014-12-31 | zł997.84 Million ≈ $274.62 Million |
zł-24.39 Million ≈ $-6.71 Million |
-0.024x | +53.89% |
| 2013-12-31 | zł520.55 Million ≈ $143.26 Million |
zł-27.59 Million ≈ $-7.59 Million |
-0.053x | -615.46% |
| 2012-12-31 | zł1.82 Billion ≈ $502.09 Million |
zł-13.51 Million ≈ $-3.72 Million |
-0.007x | +98.71% |
| 2011-12-31 | zł20.37 Million ≈ $5.60 Million |
zł-11.74 Million ≈ $-3.23 Million |
-0.576x | -794.40% |
| 2010-12-31 | zł21.72 Million ≈ $5.98 Million |
zł-1.40 Million ≈ $-385.19K |
-0.064x | -101.62% |
| 2009-12-31 | zł-74.80K ≈ $-20.59K |
zł-298.41K ≈ $-82.13K |
3.990x | -- |
About Mabion S.A.
Mabion S.A., a biopharmaceutical company, provides services as a contract development and manufacturing organization in the process development, analytics, and manufacturing of biologic medicines in Poland. It offers drug substance manufacturing, fill and finish, gene to vial end-to-end development, process development, analytics, and banking services. In addition, it offers cell line development… Read more